Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ageing-related disease therapeutics - TheraCryf

Next Previous
Search
Drug Profile

Research programme: ageing-related disease therapeutics - TheraCryf

Alternative Names: CHR 1; CHR 12; CHR 25; CHR 3; CHR 50; CHR 54; CHR 8; CHR 9; Fujimycin - TheraCryf; RDC 1; RDC 14; RDC 19; RDC 2; RDC 20; RDC 21; RDC 29; RDC 6; RDC 7; RDC 8; RDC 9

Latest Information Update: 04 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chronos Therapeutics
  • Developer TheraCryf
  • Class Small molecules
  • Mechanism of Action Cell cycle modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Neurodegenerative disorders; Postmenopausal osteoporosis; Sarcopenia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in United Kingdom
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Postmenopausal-osteoporosis in United Kingdom
  • 28 Jul 2018 No recent reports of development identified for research development in Cancer in United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top